ClinicalTrials.gg
CompletedNCT00982865Updated Oct 23, 2018Results posted

Trial of MSC1936369B in Subjects With Solid Tumors

A Phase 1 interventional study of MSC1936369B and MSC1936369B in Solid Tumors and Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Dec 2007, registered Sep 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
182
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a day, in subjects with malignant solid tumors to see how safe is treatment with MSC1936369B.

02

Conditions studied

  • Solid Tumors
  • Cancer

Browse trials for

Keywords

  • MEK inhibitor
  • Cancer
  • Solid tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 182 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed solid tumor which is locally advanced or , and either after standard therapy for the disease or for which no effective standard therapy is available. In the regimen 3, regimen 2 food-effect, and BID cohorts, the tumor type will be restricted to melanoma.
  • Age greater than or equal to (>=) 18 years
  • Has read and understands the form and is willing and able to give informed consent. Fully understands requirements of the trial and willing to comply with all trial visits and assessments

Exclusion criteria

Exclusion Criteria:

  • Bone marrow impairment as evidenced by less than (\<) 9.0 gram per deciliter (g/dL), \< 1.0*10\^9/Liter, \< 100*10\^9/Liter
  • Renal impairment as evidenced by serum creatinine > 1.5*upper limit normal (), and/or calculated \< 60 milliliter per minute (mL/min)
  • Liver function abnormality as defined by total > 1.5*ULN, or (AST)/alanine aminotransferase (ALT) > 2.5*ULN, for subjects with liver involvement AST/ALT > 5*ULN
  • > 1.5*ULN
  • Serum calcium > 1*ULN
  • History of central nervous system (CNS) , unless subject has been previously treated for , is stable by computer tomography (CT) scan without evidence of cerebral oedema, and has no requirements for or anticonvulsants
  • History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions that may hamper compliance and/or absorption of the tested product
  • Performance status (ECOG PS) greater than (>) 1
  • Known (HIV) positivity, active , or active
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    MSC1936369B Regimen 1

    Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.

    Drug: MSC1936369B

  • Experimental
    MSC1936369B Regimen 2

    MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2.

    Drug: MSC1936369B

  • Experimental
    MSC1936369B Regimen 3 once daily

    Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.

    Drug: MSC1936369B

  • Experimental
    MSC1936369B Regimen 3 twice daily (BID)

    Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.

    Drug: MSC1936369B

Interventions

  • DrugMSC1936369B

    Also known as: Pimasertib

  • DrugMSC1936369B

    Also known as: Pimasertib

  • DrugMSC1936369B

    Also known as: Pimasertib

  • DrugMSC1936369B

    Also known as: Pimasertib

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21

    DLT was defined as any of following toxicities at any dose level according to using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0(CTCAE), probably or possibly related to trial medication by investigator or sponsor: a)Any Grade 3 or more non-haematological toxicity excluding: (i)Grade 3 asymptomatic increase in liver function tests (Aspartate Aminotransferase, Alanine transaminase, Alkaline Phosphatase reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement; (ii)Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. serotonin \[5HT3\] antagonists and corticosteroids); (iii)Grade 3 diarrhoea if it is encountered despite adequate and optimal anti diarrhoea therapy; b)Grade 4 neutropenia of \>5 days duration or febrile neutropenia lasting for more than 1 day; c)Grade 4 thrombocytopenia \>1 day or grade 3 with bleeding; d)Any treatment delay \>2 weeks due to drug-related AEs.

    Time frame: Day 1 up to Day 21 of Cycle 1

Secondary outcomes

  1. Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation

    AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 253 weeks. TEAEs include both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to 253 weeks

  2. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death

    Time frame: Baseline up to 253 weeks

  3. Number of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events

    Any clinically significant changes in laboratory evaluations and vital signs were recorded as treatment emergent adverse events. The clinical laboratory parameters that were assessed included: Hematological parameters, Blood chemistry parameters, Urinalysis and the vital signs that were assessed included: Blood pressure, Heart rate, Temperature and Weight. SAF analysis was used.

    Time frame: Baseline up to 253 weeks

  4. Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1

    Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours (h) post-dose on Cycle 1(C1) Day 1 (D1), Cycle 1 Day 12 (D12) and Cycle 3 (C3) Day 1

  5. Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  6. Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)

    Cmax was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  7. Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  8. Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  9. Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  10. Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  11. Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  12. Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  13. Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  14. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  15. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  16. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  17. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  18. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  19. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  20. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  21. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  22. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  23. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  24. Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  25. Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  26. Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  27. Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  28. Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  29. Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  30. Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  31. Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  32. Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  33. Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  34. Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  35. Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  36. Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  37. Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  38. Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  39. Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1

    AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

  40. Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)

    AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  41. Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)

    AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf. Summarized data over Day 1 and Day 2 was reported.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

  42. Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily

    AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

  43. Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily

    AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

  44. Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)

    Time frame: Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3

  45. Number of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)

    Number of subjects with clinical benefit (CR, PR, or SD) and PD according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.

    Time frame: Baseline until disease progression (assessed up to end of treatment [253 weeks])

07

Results

Posted Oct 23, 2018

Participant flow

First/last subject (informed consent): December 2007/March 2012. Last subject completed: April 2016.

Participant flow — Overall Study
MilestoneMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily (BID)
Started49821534
Completed49821534
Not completed0000

Outcome measures

PrimaryNumber of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21

DLT was defined as any of following toxicities at any dose level according to using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0(CTCAE), probably or possibly related to trial medication by investigator or sponsor: a)Any Grade 3 or more non-haematological toxicity excluding: (i)Grade 3 asymptomatic increase in liver function tests (Aspartate Aminotransferase, Alanine transaminase, Alkaline Phosphatase reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement; (ii)Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. serotonin \[5HT3\] antagonists and corticosteroids); (iii)Grade 3 diarrhoea if it is encountered despite adequate and optimal anti diarrhoea therapy; b)Grade 4 neutropenia of \>5 days duration or febrile neutropenia lasting for more than 1 day; c)Grade 4 thrombocytopenia \>1 day or grade 3 with bleeding; d)Any treatment delay \>2 weeks due to drug-related AEs.

Time frame:
Day 1 up to Day 21 of Cycle 1
Reported as:
Number · Subjects
Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21
SubjectsMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 212606
SecondaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation

AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 253 weeks. TEAEs include both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to 253 weeks
Reported as:
Number · Subjects
Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation
SubjectsMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
TEAEs47821534
Serious TEAEs2345821
TEAEs leading to discontinuation132226
SecondaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death
Time frame:
Baseline up to 253 weeks
Reported as:
Number · Subjects
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death
SubjectsMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death101422
SecondaryNumber of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events

Any clinically significant changes in laboratory evaluations and vital signs were recorded as treatment emergent adverse events. The clinical laboratory parameters that were assessed included: Hematological parameters, Blood chemistry parameters, Urinalysis and the vital signs that were assessed included: Blood pressure, Heart rate, Temperature and Weight. SAF analysis was used.

Time frame:
Baseline up to 253 weeks
Reported as:
Number · Subjects
Number of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events
SubjectsMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
Haemoglobin decreased1200
Anaemia102333
Lymphopenia3700
Thrombocytopenia3621
Platelet count decreased0100
Neutropenia0401
Leukopenia0010
Pancytopenia0001
Hyponatraemia0101
Hypokalaemia41022
Hyperkalaemia1000
Hypocalcaemia2701
Hypercalcaemia0300
Hypomagnesaemia2320
Hypophosphataemia0200
Hepatic enzyme increased0100
Hepatic function abnormal0100
Alanine aminotransferase increased0102
Aspartate aminotransferase increased1102
Blood alkaline phosphatase increased1001
Hyperbilirubinaemia1100
Blood lactate dehydrogenase increased1001
Blood creatine phosphokinase increased1215
Blood creatinine increased0100
Blood 25-hydroxycholecalciferol decreased1100
Vitamin D decreased0100
Blood parathyroid hormone increased1100
Hyperglycaemia0100
C-reactive protein increased0100
Proteinuria0011
Hyperthyroidism0001
Hypoalbuminaemia3402
Weight increased0303
Weight decreased6842
Hyperthermia1501
Hypertension7514
Hypotension3120
Heart rate increased1000
Tachycardia3020
Blood potassium increased1000
SecondaryMaximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1

Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours (h) post-dose on Cycle 1(C1) Day 1 (D1), Cycle 1 Day 12 (D12) and Cycle 3 (C3) Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1
nanogram per milliliter (ng/mL)MSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D12.02 ± 41.03.20 ± 45.54.21 ± 47.96.69 ± 62.912.60 ± 15.462.32 ± 33.6126.21 ± 70.2212.96 ± 106.3357.39 ± 30.7325.99 ± 31.8428.85 ± 57.9
C1D122.92 ± 39.02.69 ± 10.16.29 ± 40.69.75 ± 63.321.93 ± 110.554.47 ± 116.2150.67 ± 78.1175.94 ± 47.5413.58 ± 9.1602.12 ± 11.0425.26 ± 71.0
C3D12.00 ± NA2.90 ± NA5.60 ± NA8.06 ± 30.310.90 ± 68.551.30 ± NA84.70 ± 78.8167.75 ± 15.5—282.44 ± 14.9652.70 ± 48.3
SecondaryMaximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)
ng/mLMSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D11.65 ± 59.22.87 ± 56.64.55 ± 113.417.26 ± 27.830.90 ± 32.639.19 ± 69.7187.98 ± 39.7321.85 ± 32.7306.63 ± 110.4373.59 ± 24.9605.11 ± 48.8539.02 ± 78.0680.87 ± 45.6990.92 ± 64.9
C1D152.28 ± 58.07.77 ± 96.24.21 ± 39.918.78 ± 32.218.47 ± 33.134.87 ± 36.8131.71 ± 14.7286.88 ± 21.8539.17 ± 37.1432.46 ± 7.6492.81 ± 117.1450.29 ± 67.4629.85 ± 71.31535.60 ± 57.1
C3D11.25 ± 5.74.30 ± NA6.56 ± 39.814.81 ± 50.116.10 ± NA—96.60 ± NA—710.94 ± 57.4532.80 ± NA568.49 ± 76.2795.86 ± 50.0773.14 ± 51.02344.91 ± 23.1
SecondaryMaximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)

Cmax was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)
ng/mLMSC1936369B 90 mgMSC1936369B 150 mg
Fasted321.14 ± 58.31158.00 ± NA
Fed305.94 ± 45.6370.70 ± NA
SecondaryMaximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily
ng/mLMSC1936369B 60 mgMSC1936369B 90 mg
C1D1241.27 ± 47.0402.77 ± 59.2
C1D15316.08 ± 34.9324.80 ± 65.8
C3D1473.27 ± 38.7376.62 ± 45.2
SecondaryMaximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily
ng/mLMSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D1132.57 ± 40.2206.46 ± 41.7263.08 ± 68.5
C1D15178.09 ± 95.0231.12 ± 44.0190.42 ± 57.6
C3D1139.60 ± 26.6157.46 ± 53.7329.28 ± 73.5
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Median · Hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1
Hours (h)MSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D11.500 (1.02 to 1.53)0.750 (0.50 to 4.25)1.500 (1.00 to 2.50)1.500 (1.00 to 2.17)1.500 (1.00 to 2.50)1.000 (0.50 to 2.00)1.500 (1.00 to 4.00)1.017 (1.00 to 2.50)1.000 (0.98 to 1.50)1.483 (0.52 to 2.17)1.017 (0.50 to 6.00)
C1D121.633 (0.50 to 2.50)0.533 (0.33 to 2.00)1.000 (1.00 to 2.50)1.000 (1.00 to 1.08)1.017 (1.00 to 1.05)1.500 (1.50 to 1.50)1.000 (0.50 to 3.92)2.000 (0.75 to 2.52)1.000 (0.50 to 4.00)1.500 (1.50 to 2.00)1.083 (0.52 to 8.00)
C3D11.52 (1.52 to 1.52)0.500 (0.50 to 0.50)1.52 (1.52 to 1.52)1.000 (0.50 to 2.67)1.517 (1.00 to 4.05)1.500 (1.50 to 1.50)1.000 (1.00 to 3.58)1.508 (0.50 to 2.52)—1.767 (1.50 to 2.03)2.000 (0.50 to 4.00)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Median · Hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)
Hours (h)MSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D11.500 (1.50 to 1.92)1.017 (0.50 to 2.50)1.500 (1.00 to 2.00)1.000 (0.50 to 24.98)0.533 (0.52 to 2.00)1.500 (0.50 to 4.00)1.000 (0.58 to 2.02)0.500 (0.50 to 1.02)1.000 (0.47 to 1.50)1.500 (0.50 to 1.58)1.250 (0.33 to 2.02)1.500 (0.58 to 4.00)1.250 (0.50 to 2.50)2.000 (0.50 to 2.50)
C1D151.500 (1.42 to 2.00)0.967 (0.52 to 1.50)2.000 (0.43 to 2.00)0.667 (0.50 to 2.50)1.008 (1.00 to 1.02)1.500 (1.50 to 4.00)1.017 (0.50 to 2.12)1.500 (0.67 to 1.52)1.250 (1.00 to 1.50)1.500 (1.50 to 2.02)2.000 (1.00 to 2.08)1.517 (1.00 to 7.92)1.250 (0.50 to 3.00)1.458 (1.00 to 2.00)
C3D11.250 (1.00 to 1.50)2.000 (2.00 to 2.00)1.258 (1.00 to 1.52)1.000 (1.00 to 1.00)2.500 (2.50 to 2.50)—1.50 (1.50 to 1.50)—0.500 (0.50 to 0.50)2.000 (2.00 to 2.00)1.042 (0.58 to 1.50)1.333 (1.00 to 2.10)1.000 (0.50 to 2.02)1.000 (1.00 to 1.67)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Median · Hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)
Hours (h)MSC1936369B 90 mgMSC1936369B 150 mg
Fasted1.600 (0.33 to 2.50)1.000 (1.00 to 1.00)
Fed2.033 (1.50 to 4.00)6.000 (6.00 to 6.00)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Median · Hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily
Hours (h)MSC1936369B 60 mgMSC1936369B 90 mg
C1D11.033 (1.00 to 1.50)1.500 (0.50 to 2.03)
C1D152.500 (1.52 to 2.50)1.492 (0.50 to 4.00)
C3D12.000 (1.50 to 2.50)1.000 (0.57 to 2.10)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Median · Hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily
Hours (h)MSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D11.500 (1.00 to 2.00)1.000 (0.50 to 4.00)0.667 (0.47 to 2.50)
C1D151.500 (1.03 to 2.00)1.500 (0.50 to 2.55)1.500 (0.97 to 4.08)
C3D11.467 (0.92 to 2.02)1.183 (0.50 to 2.07)1.467 (0.50 to 1.57)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1
hour*nanogram per milliliter (h*ng/mL)MSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D14.6 ± 431.35.2 ± 63.918.5 ± 49.822.7 ± 29.252.7 ± 74.5213.9 ± 84.0531.3 ± 55.4889.0 ± 31.91624.8 ± 36.11748.1 ± 38.82292.4 ± 52.5
C1D127.0 ± 269.86.0 ± 89.326.0 ± 55.035.9 ± 79.783.6 ± 67.7182.0 ± 125.1691.9 ± 51.4880.0 ± 45.71900.3 ± 99.71991.4 ± 19.21682.4 ± 52.4
C3D16.9 ± NA2.7 ± NA21.0 ± NA23.0 ± 38.245.2 ± 51.8113.2 ± NA334.9 ± 47.8666.3 ± 52.3—876.7 ± 20.42064.1 ± 55.0
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)
hour*ng/mLMSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D11.9 ± 331.68.2 ± 53.16.7 ± 292.967.9 ± 93.974.4 ± 19.4188.4 ± 61.7625.7 ± 20.6808.0 ± 15.7861.1 ± 112.41484.6 ± 13.02287.0 ± 96.62216.5 ± 75.73415.6 ± 44.54041.3 ± 60.8
C1D154.3 ± 228.522.2 ± 42.113.8 ± 66.979.3 ± 57.967.8 ± 53.9161.5 ± 14.1621.2 ± 12.7906.3 ± 15.41553.9 ± 122.51826.2 ± 17.91862.3 ± 96.42086.6 ± 69.93436.8 ± 64.75765.9 ± 15.3
C3D10.5 ± 76.610.2 ± NA26.2 ± 15.640.5 ± 26.946.1 ± NA—306.2 ± NA—1394.7 ± 24.61299.3 ± NA2053.6 ± 71.12171.2 ± 59.42484.5 ± 53.64906.3 ± 19.2
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)
hour*ng/mLMSC1936369B 90 mgMSC1936369B 150 mg
Fasted1509.6 ± 46.63286 ± NA
Fed1458.3 ± 41.35072.9 ± NA
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily
hour*ng/mLMSC1936369B 60 mgMSC1936369B 90 mg
C1D11229.3 ± 96.51544.9 ± 57.1
C1D151532.4 ± 80.41428.8 ± 63.6
C3D11392.3 ± 35.21122.5 ± 45.2
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily
hour*ng/mLMSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D1407.2 ± 40.7681.4 ± 43.7791.1 ± 62.3
C1D15589.3 ± 66.5838.8 ± 43.9710.3 ± 65.0
C3D1450.0 ± 57.1577.0 ± 72.51005.0 ± 25.6
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1
hour*ng/mLMSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D1136.2 ± 9.26.2 ± NA55.5 ± 321.831.4 ± 29.761.3 ± 66.9234.1 ± 70.2574.2 ± 50.0924.2 ± 32.71699.7 ± 36.11836.4 ± 42.82773.5 ± 54.7
C1D1238.3 ± 254.89.4 ± NA43.8 ± 58.747.5 ± 68.1105.6 ± 57.6206.3 ± 106.5805.6 ± 58.9960.7 ± 46.92108.2 ± 115.02257.6 ± 30.12022.8 ± 41.3
C3D115.4 ± NA—47.6 ± NA34.4 ± 37.655.5 ± 90.0134.5 ± NA489.8 ± 55.21072.1 ± 121.6—1056.0 ± 26.63477.6 ± 102.0
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)
hour*ng/mLMSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D1—23.4 ± 65.723.6 ± 22.559.1 ± 6.290.3 ± 30.8218.4 ± 62.1646.9 ± 20.7820.4 ± 15.7885.8 ± 111.01525.6 ± 13.22424.2 ± 109.72287.8 ± 77.43602.2 ± 46.24300.3 ± 54.2
C1D1515.7 ± 10.633.3 ± 45.821.9 ± 91.5102.0 ± 63.689.7 ± 85.9172.2 ± 9.0669.1 ± 10.5933.9 ± 15.41665.2 ± 132.11893.2 ± 17.52129.0 ± 123.72029.9 ± 63.33900.8 ± 64.36232.1 ± 7.0
C3D1—15.4 ± NA41.2 ± 41.449.5 ± 17.458.1 ± NA—415.6 ± NA—1655.1 ± 19.11584.8 ± NA2461.3 ± 64.32796.2 ± 59.33452.9 ± 61.65651.1 ± 23.5
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)
hour*ng/mLMSC1936369B 90 mgMSC1936369B 150 mg
Fasted1580.6 ± 48.73344.3 ± NA
Fed1495.7 ± 41.85633.8 ± NA
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily
hour*ng/mLMSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D1527.6 ± 57.4742.3 ± 47.1939.9 ± 67.3
C1D15674.1 ± 73.61004.2 ± 46.4978.4 ± 63.7
C3D1696.0 ± 101.4700.8 ± 79.01285.7 ± 29.0
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily
hour*ng/mLMSC1936369B 60 mgMSC1936369B 90 mg
C1D11253.1 ± 96.91581.4 ± 56.6
C1D151753.9 ± 93.11517.1 ± 65.6
C3D11597.0 ± 50.71400.3 ± 53.0
SecondaryApparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · Hours (h)
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1
Hours (h)MSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D1———3.346 ± NA3.405 ± 52.14.599 ± 29.14.781 ± 39.45.389 ± 9.45.335 ± 23.65.351 ± 15.95.247 ± 17.1
C1D12———4.985 ± 123.59.249 ± NA3.236 ± 19.46.750 ± 21.54.688 ± 60.46.926 ± 33.65.672 ± 15.43.964 ± 44.7
C3D1————2.959 ± NA2.811 ± NA—2.931 ± NA—2.842 ± NA3.038 ± 3.4
SecondaryApparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Hours (h)
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)
Hours (h)MSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D1————2.594 ± 5.05.119 ± 30.55.115 ± 6.64.187 ± 10.33.305 ± 84.04.826 ± 14.05.057 ± 45.34.904 ± 18.85.641 ± 21.64.313 ± 29.6
C1D15———2.941 ± NA2.335 ± NA4.443 ± 67.36.646 ± 19.55.277 ± 8.06.441 ± 28.45.193 ± 11.14.851 ± 7.95.479 ± 14.16.016 ± 18.94.847 ± 16.4
C3D1———2.732 ± NA————3.477 ± 11.02.853 ± NA2.863 ± 22.02.418 ± 25.22.628 ± 9.42.260 ± 34.4
SecondaryApparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · Hour (h)
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)
Hour (h)MSC1936369B 90 mgMSC1936369B 150 mg
Fasted4.898 ± 36.74.452 ± NA
Fed4.534 ± 18.36.123 ± NA
SecondaryApparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Hour (h)
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily
Hour (h)MSC1936369B 60 mgMSC1936369B 90 mg
C1D14.236 ± 1.34.097 ± 33.5
C1D155.259 ± 14.85.599 ± 30.1
C3D11.780 ± NA2.680 ± 21.1
SecondaryApparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · Hour (h)
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily
Hour (h)MSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D12.050 ± NA2.509 ± 25.12.814 ± 20.2
C1D152.890 ± 23.83.265 ± 18.63.210 ± 23.8
C3D13.144 ± NA2.636 ± 17.03.260 ± 10.6
SecondaryTotal Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter per hour
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1
Liter per hourMSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D1———132.69 ± NA114.26 ± 66.959.80 ± 70.248.76 ± 50.048.69 ± 32.740.01 ± 36.150.45 ± 41.247.82 ± 53.3
C1D12———70.60 ± 77.344.55 ± NA62.53 ± 92.637.49 ± 55.249.37 ± 43.835.80 ± 99.750.88 ± 19.661.44 ± 42.3
C3D1————217.56 ± NA104.07 ± NA—82.35 ± NA—107.06 ± NA72.25 ± 35.7
SecondaryTotal Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter per hour
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)
Liter per hourMSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D1————90.76 ± 18.364.09 ± 62.143.28 ± 20.754.85 ± 15.776.77 ± 111.061.61 ± 13.249.50 ± 109.765.57 ± 77.454.13 ± 46.260.63 ± 53.4
C1D15———59.55 ± NA134.9 ± NA86.72 ± 12.545.10 ± 12.749.65 ± 15.443.76 ± 122.451.47 ± 17.992.42 ± 84.181.22 ± 65.453.49 ± 64.342.20 ± 5.9
C3D1———89.34 ± NA————41.08 ± 19.159.31 ± NA48.76 ± 64.361.04 ± 53.072.33 ± 63.844.23 ± 37.5
SecondaryTotal Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · Liter per hour
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)
Liter per hourMSC1936369B 90 mgMSC1936369B 150 mg
Fasted56.94 ± 48.744.85 ± NA
Fed60.17 ± 41.826.62 ± NA
SecondaryTotal Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter per hour
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily
Liter per hourMSC1936369B 60 mgMSC1936369B 90 mg
C1D147.88 ± 96.956.91 ± 56.6
C1D1548.31 ± 103.962.85 ± 63.6
C3D153.36 ± NA75.63 ± 59.6
SecondaryTotal Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · Liter per hour
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily
Liter per hourMSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D1114.82 ± NA80.83 ± 47.183.86 ± 67.2
C1D1571.44 ± 69.366.89 ± 52.194.48 ± 71.2
C3D1126.1 ± NA103.3 ± 66.977.09 ± 21.0
SecondaryApparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1
LiterMSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D1———640.60 ± NA561.27 ± 12.9396.76 ± 86.7336.32 ± 78.8378.56 ± 23.0307.90 ± 43.1389.49 ± 28.6361.99 ± 43.0
C1D12———507.8 ± 28.3594.5 ± NA291.9 ± 73.0365.1 ± 35.0333.9 ± 65.1357.8 ± 53.7416.3 ± 35.8351.4 ± 37.5
C3D1————928.91 ± NA422.04 ± NA—348.19 ± NA—438.91 ± NA316.63 ± 33.9
SecondaryApparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)
LiterMSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D1————339.58 ± 13.2473.32 ± 81.2319.40 ± 27.0331.36 ± 13.3366.00 ± 22.8428.99 ± 22.7361.12 ± 58.1463.92 ± 68.7440.55 ± 41.7377.28 ± 42.4
C1D15———252.7 ± NA454.6 ± NA555.9 ± 84.7432.5 ± 30.7378.0 ± 23.6406.6 ± 76.5385.6 ± 25.9646.9 ± 96.3642.1 ± 63.5464.2 ± 64.9295.1 ± 13.4
C3D1———352.10 ± NA————206.07 ± 30.5244.16 ± NA201.39 ± 95.6212.92 ± 34.4274.24 ± 53.8144.24 ± 79.1
SecondaryApparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)
LiterMSC1936369B 90 mgMSC1936369B 150 mg
Fasted402.4 ± 49.0288.1 ± NA
Fed393.6 ± 40.5235.2 ± NA
SecondaryApparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily
LiterMSC1936369B 60 mgMSC1936369B 90 mg
C1D1292.61 ± 99.0336.38 ± 47.1
C1D15366.5 ± 131.6507.7 ± 66.0
C3D1137.0 ± NA292.5 ± 47.3
SecondaryApparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily
LiterMSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D1339.51 ± NA292.59 ± 42.3340.43 ± 57.7
C1D15297.9 ± 57.8315.0 ± 59.4437.6 ± 59.1
C3D1571.8 ± NA392.9 ± 81.9362.6 ± 10.2
SecondaryArea Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Reported as:
Geometric mean · Percentage of AUC 0-∞
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1
Percentage of AUC 0-∞MSC1936369B 1 mgMSC1936369B 1.5 mgMSC1936369B 2.5 mgMSC1936369B 3.5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mg
C1D181.33 ± 21.242.23 ± NA43.45 ± 79.826.80 ± 27.313.08 ± 47.75.31 ± 174.35.39 ± 112.53.52 ± 52.04.08 ± 47.34.09 ± 75.25.28 ± 155.8
C1D1250.60 ± 8.633.84 ± NA40.60 ± 5.621.27 ± 56.819.82 ± 37.67.83 ± 193.66.57 ± 45.08.17 ± 29.16.56 ± 185.57.94 ± 131.82.97 ± 137.2
C3D155.15 ± NA—55.79 ± NA32.85 ± 14.321.27 ± 33.115.84 ± NA28.06 ± 30.627.67 ± 126.0—16.54 ± 30.226.05 ± 98.7
SecondaryArea Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · Percentage of AUC 0-∞
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)
Percentage of AUC 0-∞MSC1936369B 1 mgMSC1936369B 2 mgMSC1936369B 3.5 mgMSC1936369B 5 mgMSC1936369B 7 mgMSC1936369B 14 mgMSC1936369B 28 mgMSC1936369B 45 mgMSC1936369B 68 mgMSC1936369B 94 mgMSC1936369B 120 mgMSC1936369B 150 mgMSC1936369B 195 mgMSC1936369B 255 mg
C1D1—55.78 ± 11.031.63 ± 31.227.25 ± 15.215.10 ± 63.912.17 ± 59.83.29 ± 3.71.46 ± 30.82.66 ± 40.82.60 ± 33.42.94 ± 181.02.64 ± 68.34.36 ± 76.23.57 ± 149.3
C1D1540.86 ± 2.933.34 ± 6.435.29 ± 30.021.93 ± 20.219.45 ± 107.412.45 ± 58.06.89 ± 32.92.96 ± 1.95.00 ± 141.43.40 ± 33.95.82 ± 251.84.82 ± 82.95.77 ± 72.85.22 ± 112.2
C3D1—33.93 ± NA33.77 ± 47.717.27 ± 45.020.68 ± NA—26.32 ± NA—15.35 ± 29.718.02 ± NA16.22 ± 26.917.54 ± 83.423.45 ± 59.411.15 ± 77.4
SecondaryArea Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf. Summarized data over Day 1 and Day 2 was reported.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Reported as:
Geometric mean · Percentage of AUC 0-∞
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)
Percentage of AUC 0-∞MSC1936369B 90 mgMSC1936369B 150 mg
Fasted2.54 ± 149.81.74 ± NA
Fed2.21 ± 56.39.96 ± NA
SecondaryArea Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Reported as:
Geometric mean · percentage of AUC 0-∞
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily
percentage of AUC 0-∞MSC1936369B 60 mgMSC1936369B 90 mg
C1D11.88 ± 16.22.11 ± 50.0
C1D157.95 ± 149.34.28 ± 85.0
C3D19.11 ± 171.317.56 ± 50.9
SecondaryArea Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Reported as:
Geometric mean · Percentage of AUC 0-∞
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily
Percentage of AUC 0-∞MSC1936369B 45 mgMSC1936369B 60 mgMSC1936369B 75 mg
C1D116.82 ± 128.47.70 ± 58.310.90 ± 68.3
C1D1511.78 ± 42.814.14 ± 51.419.19 ± 79.3
C3D130.63 ± 70.716.43 ± 37.521.34 ± 21.8
SecondaryPhosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
Time frame:
Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3
Reported as:
Mean · fold change
Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
fold changeMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once DailyMSC1936369B Regimen 3 Twice Daily
C1D1, Pre-dose (pERK)4.524 ± 1.8393.937 ± 1.6624.121 ± 1.7433.629 ± 1.491
C1D1, 2 h post-dose (pERK)1.235 ± 0.2951.305 ± 0.7551.178 ± 0.1941.249 ± 0.219
C1D1, 4 h post-dose (pERK)3.828 ± 1.7153.422 ± 1.902——
C1D1, 8 h post-dose (pERK)1.454 ± 0.5151.454 ± 0.4031.878 ± 0.8361.821 ± 0.514
C1D2, Pre-dose (pERK)2.853 ± 1.3992.411 ± 1.0313.081 ± 1.2492.069 ± 0.748
C1D5, Pre-dose (pERK)2.722 ± 1.326———
C1D8, Pre-dose (pERK)4.48 ± 2.1192.868 ± 1.4732.541 ± 1.3382.235 ± 0.739
C1D12-15, Pre-dose (pERK)3.257 ± 1.6713.265 ± 1.8453.241 ± 2.2492.16 ± 0.814
C1D12-15, 2 h Post-dose (pERK)1.252 ± 0.2171.293 ± 0.4471.471 ± 0.5291.315 ± 0.218
C1D12-15, 8 h Post-dose (pERK)1.514 ± 0.3911.653 ± 0.5711.902 ± 0.871.98 ± 0.827
C1D12-15, 24 h Post-dose (pERK)2.768 ± 1.5942.476 ± 0.9582.598 ± 1.1852.043 ± 0.76
C3D1, Pre-dose (pERK)5.179 ± 2.1513.716 ± 1.875——
C3D1, 2 h Post-dose (pERK)1.795 ± 0.6871.288 ± 0.327——
C3D1, 4 h Post-dose (pERK)3.106 ± 0.4612.688 ± 2.065——
C1D1, Pre-dose (Tot ERK)1.1 ± 0.4681.075 ± 0.251.02 ± 0.1691.086 ± 0.277
C1D1, 2 h post-dose (Tot ERK)1.063 ± 0.2151.069 ± 0.2471.078 ± 0.1511.079 ± 0.193
C1D1, 4 h post-dose (Tot ERK)1.059 ± 0.6211.012 ± 0.286——
C1D1, 8 h post-dose (Tot ERK)1.058 ± 0.161.095 ± 0.311.078 ± 0.1431.098 ± 0.161
C1D2, Pre-dose (Tot ERK)1.075 ± 0.1031.13 ± 0.4551.013 ± 0.2731.108 ± 0.154
C1D5, Pre-dose (Tot ERK)1.163 ± 0.146———
C1D8, Pre-dose (Tot ERK)1.233 ± 0.6741.108 ± 0.3530.944 ± 0.1171.049 ± 0.133
C1D12-15, Pre-dose (Tot ERK)1.223 ± 0.4761.118 ± 0.2681.333 ± 0.8781.047 ± 0.144
C1D12-15, 2 h Post-dose (Tot ERK)1.04 ± 0.1021.125 ± 0.341.335 ± 0.7541.059 ± 0.14
C1D12-15, 8 h Post-dose (Tot ERK)0.994 ± 0.1651.041 ± 0.2371.044 ± 0.2381.026 ± 0.146
C1D12-15, 24 h Post-dose (Tot ERK)1.047 ± 0.1531.045 ± 0.1831.048 ± 0.1391.068 ± 0.141
C3D1, Pre-dose (Tot ERK)1.074 ± 0.341.138 ± 0.306——
C3D1, 2 h Post-dose (Tot ERK)1.087 ± 0.4131.251 ± 0.29——
C3D1, 4 h Post-dose (Tot ERK)0.674 ± 0.3041.052 ± 0.182——
SecondaryNumber of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)

Number of subjects with clinical benefit (CR, PR, or SD) and PD according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.

Time frame:
Baseline until disease progression (assessed up to end of treatment [253 weeks])
Reported as:
Number · Subjects
Number of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)
SubjectsMSC1936369B Regimen 1MSC1936369B Regimen 2 and Regimen 2 Food EffectMSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
CR0001
PR0426
SD1934914
PD2033412

Adverse events

Collected over Baseline up to 253 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSC1936369B Regimen 1—23/49 (46.9%)47/49 (95.9%)
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)—45/82 (54.9%)80/82 (97.6%)
MSC1936369B Regimen 3 Once Daily (QD)—8/15 (53.3%)15/15 (100%)
MSC1936369B Regimen 3 Twice Daily—21/34 (61.8%)34/34 (100%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
General physical health deteriorationGeneral disorders7/4913/822/152/34
DiarrhoeaGastrointestinal disorders0/492/822/154/34
NauseaGastrointestinal disorders0/490/822/151/34
HeadacheNervous system disorders0/491/822/151/34
Dermatitis acneiformSkin and subcutaneous tissue disorders0/492/820/153/34
PyrexiaGeneral disorders2/493/821/152/34
Vision blurredEye disorders0/490/821/150/34
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/494/821/150/34
ThrombophlebitisVascular disorders1/490/821/150/34
DehydrationMetabolism and nutrition disorders0/491/821/150/34
Most frequent other events
Showing 10 of 390
Most frequent other events
EventMSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice Daily
DiarrhoeaGastrointestinal disorders25/4946/8214/1529/34
Oedema peripheralGeneral disorders12/4930/829/1521/34
Macular detachmentEye disorders3/4914/829/1516/34
AstheniaGeneral disorders27/4938/828/1512/34
Dermatitis acneiformSkin and subcutaneous tissue disorders7/4919/827/1512/34
NauseaGastrointestinal disorders21/4926/826/1515/34
RashSkin and subcutaneous tissue disorders9/4918/826/1514/34
PruritusSkin and subcutaneous tissue disorders6/4913/826/156/34
PyrexiaGeneral disorders9/4913/823/1512/34
VomitingGastrointestinal disorders15/4928/822/1511/34

Baseline characteristics

Safety analysis set included all subjects who received at least 1 dose of MSC1936369B treatment.

Age, Customized
Age, Customized(Participants)MSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice DailyTotal
>= 18 - <45 Years4104725
>=45 - <65 Years3049913101
>=65 Years152321454
Sex: Female, Male
Sex: Female, Male(Participants)MSC1936369B Regimen 1MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)MSC1936369B Regimen 3 Once Daily (QD)MSC1936369B Regimen 3 Twice DailyTotal
Female203091170
Male2952623110
08

Study locations

9 sites
  • Westmead Hospital
    Westmead, Australia
  • Jules Bordet Institute
    Brussels, B-1000, Belgium
  • Ghent University Hospital
    Ghent, Belgium
  • Institute Bergonié
    Bordeaux, France
  • Hôpital Beaujon
    Paris, 92118, France
  • Hopital Saint Louis
    Paris, France
  • Centre Eugène Marquis
    Rennes, France
  • Institute Claudius Regaud
    Toulouse, 03 31052, France
  • Netherlands Cancer Institute - Antonie van Leeuwenhoek Hospital
    Amsterdam, Netherlands
09

References and documents

Publications

  • Lebbe C, Italiano A, Houede N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Target Oncol. 2021 Jan;16(1):47-57. doi: 10.1007/s11523-020-00767-1. PubMed 33211315 ↗
  • Delord JP, Italiano A, Awada A, Aftimos P, Houede N, Lebbe C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. PubMed 33170484 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2007 to primary completion in Mar 2013, 63 months.

Results were first posted in Oct 2018, 5 years 6 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 63 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2009
First posted
Sep 23, 2009
StartActual
Dec 31, 2007
Primary completionActual
Mar 31, 2013
CompletionActual
Apr 30, 2016
Results first posted
Oct 23, 2018
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00982865
Collaborators
Merck Serono S.A., Geneva
Responsible party
Sponsor
First posted
Sep 23, 2009
Start date
Dec 31, 2007
Primary completion
Mar 31, 2013
Completion
Apr 30, 2016
Results posted
Oct 23, 2018
Last update
Oct 23, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion